Sofinnova Partners is a European venture capital firm focused on life sciences, healthcare, and sustainability. Based in Paris, London, and Milan, the firm manages over €4bn and has backed more than 500 companies since 1972.
The Series A round included backing from British Patient Capital, F-Prime Capital, and Sofinnova Partners.
"Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies. Their vision combined with research excellence provides the best foundation to develop treatments that could be gamechangers for millions of patients worldwide. Through Future Fund: Breakthrough, we are delighted to support this truly innovative British business with the funding to take the business to the next level."
The life sciences software provider raised the capital from Horizons Ventures and Sofinnova Partners to fund commercial growth.
"But to maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources."
The investment round was co-led by Sofinnova Partners and Redmile Group to fund global expansion and research programmes.
"This is a transformational investment from two of the most respected specialist investment funds in the industry and a recognition of the untapped potential of the pioneering product and market development carried out by the Company to date"
